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Summary: The main literature concerning the physiology and biochemistry as well as the pathophysiology and pathobio-
chemistry of magnesium is reviewed, including:
Distribution and physico-chemical state of magnesium in the extracellular and intracellular fluid as well as in the sub-
cellular organelles (membranes, mitochondria, microsomes, ribosomes).
Intestinal resorption, transport across membranes and excretion by the kidney.
Hormonal regulation of magnesium distribution and its clinical disturbances.
Biochemical mechanism and the clinical effects of hypo- and hypermagnesemia.
Magnesium-Stoffwechsel: Eine Übersicht
Zusammenfassung: Die wichtigsten Arbeiten über die Physiologie und Biochemie sowie Pathophysiologie und Patho-
biochemie des Magnesiums werden dargestellt.
Die Darstellung bezieht sich im wesentlichen auf:
Die Verteilung und den physikalisch-chemischen Zustand des Mg in der extrazellulären und intrazellulären Flüssigkeit
und in den Zellorgänellen (Membranen, Mitochondrien, Mikrosomen, Ribosomen).
Die Resorption im Darm, Transport durch Membranen und die Ausscheidung durch die Niere.
Die hormonale Regulation der Mg-Verteilung und ihre klinischen Störungen.
Biochemische Mechanismen und klinische Erscheinungen bei Hypo- und Hypermagnesiämie.
Introduction Magnesium analysis
Magnesium is one of the most vital elements of the body. Several methods are available for the determination of
It activates about 300 enzymes aiid is involved in the magnesium. At present atomic absorption spectrometry
regulation of cellular permeability and neuromuscular is the most convenient method, both in clinical chemistry
excitability. Probably magnesium deserves more clinical and in research. Easy to handle, with a high sensitivity
attention thai! is usually given. This review is chiefly and specificity for magnesium, the method is relatively
concerned with the fundamentals-of magnesium meta- precise. Spectrophotometric determination of magnesium
bolism and the related clinical aspects. with dyes of the carboxyanilide type or methyl-thymol-
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blue yields values different from atomic absorption
spectrometry. At magnesium concentrations above
0.86 mmol/1 the colorimetric methods give higiher values
and below 0.86 mmol/1 smaller values than are obtained
with atomic absorption spectrometry. The formerly most
popular titan yellow method should no longer be used,
since the Mg-dye complex is unstable and the results show
a considerable variance (1).
Other methods of magnesium determination have been
introduced for special purposes. In renal physiology, the
sample volume obtained by micropuncture is in the
range of nl and the magnesium content to be deter-
mined in the pmol range. Electron probe analysis (2)
and helium glow photometry (3) have been success-
fully used. More recently a fluorometric method with
N'N'-bis-salicylidene 2'3 diaminobenzofuran [SABF] (4)
has been adapted for this ultramicro range (5). How-
ever, all the methods mentioned have some disadvant-
ages. The instruments for electron probe analysis and
helium glow photometry can only be operated by an
experienced specialist. The SABF method is hampered
by the interference of phosphate.
Distribution of magnesium in the organism
The ideal male body with a weight of 70 kg contains
1.18 kg calcium, 146 g potassium, 104 g sodium and
24 g magnesium (6). Approximately one half of the
total magnesium content is in bones, three quarters
of this are adsorbed to apatite. This magnesium fraction
is in equilibrium with ionized magnesium of the extra-
cellular fluid and can be readily mobilized in a state
of magnesium deficiency. The ability to mobilize
bone magnesium decreases with increasing age. About
95% of the other magnesium is localized in the intra-
cellular space. After potassium, magnesium is the most
abundant intracellular element. For literature see
Hänze (6).
In an investigation with 5100 patients, serum magnesium
was determined routinely by atomic absorption spectro-
metry. A normal value of 0.89 ± 0.08 mmol/1 (± 1 SD)
was found. 90% of the values fell in the range between
0.75 and 1.0 mmol/1 (7). A compilation of normal
magnesium values in serum obtained with different
methods such as complexometric titration, fluoro-
metry with 8-hydroxyquinoline and flame photometry
was published recently (8). The magnesium content of
the human organs varies between 3 and 9 mmpl/kg
wet .weight (9,10). As can be seen in table 1, the highest
non-osseous magnesium content can be found in muscle
and heart. Values for other mammals are not different
from those for humans (9).
The physicochemical state of plasma magnesium in man
is listed in table 2. As can be seen, 55% of magnesium
is "free", i.e. in the ionized form. 32% of magnesium is
protein bound, mostly to albumin. The remaining mag-
Tab. 1. Mg content of various human organs,
a = data according to Walser (9).
b = data according to lyengar et al. (10).
Mg
jmmol/1]
a b
Plasma
Serum
Erythrocytes
Brain
Stomach, intestine
Liver
Lung
Kidney
Heart
Muscle
Lymphnodes
Spleen
0.87
0.89 0.89
2.55 2.35
[mmol/kg
wet weight]
5.8 6.99
6.17
7.3 7.89
3J 6.48
• 4.3 8.63
7.2 8.82
8.9 8.81
7.36
6.5 6.47
Tab. 2. Physico-chemical state of magnesium in plasma according
to the data of Walser (9).
Protein (Albumin) bound magnesium
Free magnesium
MgHP04
Mg citrate
Other Mg^complexes
32%
55%
Tab. 3. Subcellular distribution of magnesium in rat liver. The
references are a) Thiers &. Vallee (12), b) Griswold
& Pace (11), c) George & Heaton (13), normal diet;
d) George & Heaton, magnesium deficient diet (13).
Magnesium
Nuclei
Mito-
chondria
Micro so me s
Supernatant
(Cytosol]
[mmol/
gN]
a
0.345
0.424
0.407
0.218
[%of
total
Mg]
a
47.8
17.4
13.7
19.2
[mmol/
gN]
b
0.334
0.294
0.442
0.244
[%of
total
Mg]
b
13.4
21.8
48
12.8
[mmol/
gN]
c
0.263
0,153
0.374
0.210
[mmol/
gN]
d
0.325
0.140
0.370
0.201
nesium is cömplexed with phosphate, citrate and other
agents (9).
Within the cell, magnesium is not distributed homo-
geneously. In table 3, the magnesium content of various
subcellular fractions of rat liver is summarized. Different
results were obtained, depending on the thoroughness
of homogenization. It seems that most of the cellular
magnesium is bound to microsomes(ll, 12, 13). Inter-
estingly, the magnesium content of mitochondria and
the amount of mitochondria per cell is reduced, after
magnesium deprivation (13),
Even within a single cell fraction, the distribution of
magnesium is not homogeneous. In rat liver mito-
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chondria, 4% of the total magnesium content is in
the outer membrane, 50% in the intermembraneous
compartment, 5% in the inner membrane and 41%
in the matrix (14). The high magnesium content in
the intermembranous compartment is explained by a
high magnesium binding capacity of certain proteins.
One protein with a molecular weight of 150 000
daltons binds 300 nmol/mg protein with a dissociation
constant of 0.37 mmol/1. Another protein with a mole-
cular weight of 100 000 daltons binds 20 nmol/mg
protein with a dissociation constant of 1.0 μτηοΐ/l
(15). In addition, magnesium is bound by phospho-
lipids, not only in mitochondria but also in the endo-
plasmic reticulum. The nucleic acid of the endo-
plasmic reticulum and the ribosomes also binds magne-
sium. In the cytosol, ionized magnesium is in equi-
librium with various magnesium complexes (see below).
Biochemical functions of magnesium
Effect on enzyme reactions
One of the main effects of magnesium is the activation
of enzymes which is a result of its ability to form
chelates. At present, approximately 300 enzymes are
known that need magnesium for activation. One
example is the group of enzymes involved in reactions
with ATP. If one plots the catalytic activity of a magne-
sium-dependent enzyme as a function of pMg, a sym-
metrical bell-shaped curve is obtained with a pMg
optimum in the range of pMg = 3. (Analogous to the
definition of pH, pMg = - log [Mg2+]). Such a bell
shaped curve (fig. 1) is the sum of two sigmoid curves:
one curve expressing the activation and another the in-
hibition of the enzyme (16). Enzyme inhibition is
caused by unspecific binding of magnesium to the
enzyme protein, e.g. to the tyrosyl residues at high
magnesium concentrations.
II
The activation of enzymes by magnesium is thought to
occur according to the following mechanisms:
l.Mg +S^MgS E = enzyme
S = substrate
MgS + E^ MgES -» MgP + E P = reaction product
In this sequence, magnesium is reacting with the sub-
strate. It reduces the high negative charge of the
subtrate which is normally ATP4". As a consequence
MgS, as the true substrate, is reacting with the enzyme.
This type of reaction also occurs with hexokinase and
phosphogjy cerate kinase (18).
2.Mg +E
MgE + S MgSE -> MgE + P
Fig. 1. Activity of a magnesium-dependent enzyme as a function
of pMg. Curve I indicates the activation, curve II shows the
inhibition of the enzyme as a function of pMg.
In this reaction sequence, magnesium first reacts with
the enzyme. This is followed by a conform ational
change of the enzyme, resulting in its activation.
Thereafter, the substrate is bound to the enzyme.
Examples of this type of reaction are the enolase, pyru-
vate kinase, and pyrophosphatase (18). The binding
of S to MgE can also be accomplished with participation
of magnesium. In both types of reaction, magnesium
facilitates the reaction by polarization as an additional
effect (for review see G nther (19)). Also, a combina-
tion of both types of reaction is possible. In the FI -
ATPase reaction of E. coli, Mg ATP is the substrate.
In addition, the enzyme is activated by magnesium (20).
Another effect of magnesium is to change the equi-
librium of a reaction; this arises when magnesium forms
complexes with the substrate and reaction product,
which have different stabilities; alternatively the free
substrate and its magnesium complex may have different
affinities for the enzyme.
Reaction of magnesium with intracellular
structures
Magnesium and calcium form stable complexes with
phospholipids that are an integral part of the cell mem-
branes. For phosphatidylserine, the stability constant
of magnesium is 2 X 104 (mol/1)"1 (21). The stability
constant for Mg ATP is in the same range. Calcium
forms complexes of similar stability with phosphatidyl-
serine. No data are available for other membrane-
located phospholipids. However, it can be assumed,
that with regard to magnesium and calcium concen-
trations in the intra- and extracellular space, most of
the phosphate groups in phospholipids are occupied
with magnesium and calcium. On the cytoplasmic
side of the plasma membrane, not only magnesium
but also poly amines could be bound. The binding of
divalent cations to the phospholipids decreases their
mobility within the membrane, thus decreasing
membrane fluidity (22).
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As a consequence, membrane permeability may be
decreased and the reaction of a hormone-receptor-
complex of the cell membrane with a membrane-
bound enzyme may be altered. In addition, the activity
of membrane-bound, phospholipid-dependent enzymes
should also be changed. Interestingly, in JE. coli grown
in magnesium deficient media, membrane permeability
increased and the composition of phospholipids was
changed (23). This defect could not be normalized
by the addition of magnesium alone, but requires
protein synthesis (24).
The binding of magnesium to nucleic acids by forming
outer sphere complexes reduces the repelling action of
the negatively charged phosphate groups. A cross^
linking of contiguous nucleic acid helixes by magnesium
is unlikely because of the relatively wide distance
between two phosphate residues. However, any folding
of a polynucleotide chain which brings two phosphate
residues more closely together, may result in the forma-
tion of Mg2+ inner sphere complexes. Moreover, the
presence of Mg2+ will favour the folding of poly-
nucleotide chains. Thus the formation of the native
tRNA conformation, which requires a very close folding
of the nucleotide chain, is greatly facilitated by Mg2+
(25). For Example, one mol phenylalanine-t-RNA binds
four moles of Mg2"1" and two moles of spermine. Their
exact location within the t-RNA molecule has been
determined (26). Other nucleic acids, ribosomes and
ribosomal RNA bind up to 0.5 magnesium/phosphate,
depending on ionic strength and polyamine and
magnesium concentrations (27). tRNA^61 has a strong
Mg2+ binding site (K = 3 - 104 (mol/1)"1) and weak
binding sites with K = 4 · 102 (mol/1)"1 (28). This
explains why the formation of the initiation complex in
protein synthesis also depends on magnesium ions (29).
After removal of magnesium, the conformation of ribo-
somes is changed (30), and they disintegrate and
disappear (31).
To summarize, it is evident that due to its additive
actions on enzymes and cellular structures magnesium
is involved in most reactions of carbohydrate, lipid,
nucleic acid and protein metabolism. Therefore all
energy producing reactions (oxidative phosphorylation)
as well as all energy consuming reactions (contraction)
are dependent on magnesium.
Intracellular concentration of magnesium ions
The intracellular space is divided by membranes (endo-
plasmic reticulum, sarcoplasmic reticulum, mitochondria,
golgi vesicles, lysosomes etc.) within several compart-
ments. Transport and exchange of calcium and also
magnesium takes place in these compartments. In addi·.
tion, cations are concentrated near the surface of poly r
anions and near the surface of electrically charged
membranes (Don«0w-effect). Therefore within the
cytosol, the magnesium ion concentration may exhibit
considerable local differences. The value for the intra-
cellular magnesium ion concentration represents only
an integral value.
The intracellular concentration of free and complexed
magnesium has been evaluated by different methods:
1. Magnesium ion concentration has been calculated,
taking into consideration a) the stability constants of
the main intracellular magnesium chelatofs; b) the
intracellular magnesium concentration; c) intracellular
pH, and d) intracellular ionic strength (32).
2. The magnesium-dependent equilibrium constant of
a suitable enzymatic reaction (aconitate hydratase) was
calculated from the intracellular concentration of the
reaction components and compared with the magnesium
dependence of the equilibrium constant in vitro (33).
3. The activation of the magnesium-dependent isocitric
dehydrogenase by known magnesium concentrations
has been compared with the activation by the unknown
magnesium concentration of tissue extracts (34).
4. Magnesium ion activity has been determined directly
in tissue extracts by a magnesium-sensitive electrode.
The interference by sodium and potassium has been con-
sidered (35).
The values obtained with the different methods resulted
in a magnesium ion concentration of about 10~3 mol/1
(pMg = 3). This means that approximately 80% of total
cellular magnesium is bound. Free and bound magnesium
form a "magnesium buffer system" keeping the free
magnesium ion concentration relatively constant (33,
36). At this pMg, most of the magnesium dependent
enzymes are optimally activated or nearly so (19). This
intracellular magnesium ion concentration is so low that
polyamines may be involved in the functions of magne-
sium in protein synthesis (37).
The low intracellular magnesium^ion concentration pre-
vents miscoding (38—40) and facilitates the action of
the initiation and dissociation factors in protein synthesis
(41-43).
Magnesium transport
In nongrowing cells and in most organs of adult animals,
the transport rate of magnesium is low and difficult to
measure by conventional chemical techniques. There-
fore, the mechanism of magnesium transport has been
frequently investigated using 28Mg. However, the use
of 28Mg was hampered by a) a short half life time of 21
hours, b) a relatively low specific activity, and c) limited
availability. It has been shown in rabbits.and rats that
after administration of 28Mg the isotope was incorporated
into all organs (44—46). The exchange of 28Mg in liver,
kidney and heart was rapid, while the turnover in
muscle, brain and erythrocytes was relatively slow. For
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the isolated perfused heart, it has been found that 98%
of the magnesium content was exchanged with the same
rate constant. The exchange followed MIchaelis-Menten
kinetics. The Km value was 0.57 mmol/1 (47). KB cells
showed a similar behaviour. The Km values averaged
0.1 mmol/1. The 28Mg exchange was specific and could
not be inhibited by calcium. Inhibition of respiration by
cyanide, of oxidative phosphorylation by m-chlorophenyl
carbonylcyanide hydrazone (CCCP) and of (Na* + K"*>
ATPase by ouabain decreased the exchange of 28Mg (48).
Analogous results have been obtained with/?, coll
(49,50).
From these results it may be concluded that 28Mg is
taken up in an energy-dependent process by a "carrier"
or a "channel". Since the magnesium transport of
growing E. coli is genetically determined (51, 52) it
may be assumed that magnesium transport is facilitated
or controlled by a specific protein, at least in these
cells. Whether the magnesium transport of nongrowing
cells is an "active transport" cannot be decided at the
moment. Under these conditions, the carrier-mediated
exchange of magnesium does not result in net uptake,
which is in contrast to the growing cells (53,54). While
growing bacteria concentrate magnesium against a
gradient of up to 1:1000, the magnesium gradient of
animal cells is approximately only 1:3.
Therefore, the intracellular magnesium ion concen-
tration in animal cells is likely to be very similar
to the extracellular concentration, so that there may
be no significant magnesium gradient (33).
As already pointed out, magnesium is not only trans-
ported into the cell but is also transported within the
cell into the different cellular organelles. In experiments
with isolated mitochondria and endoplasmic or sarco-
plasmic reticulum, the existence of magnesium trans-
port has been demonstrated. Mitochondria showed an
energy-dependent magnesium uptake (55, 56). The
magnesium efflux of mitochondria was also dependent
on respiration, which obviously is dependent on mito-
chondrial calcium turnover (57), for review see Bygrave
(58). Microsomes and reconstituted phospholipid
vesicles containing Ca-ATPase exchanged two calcium
ions against one magnesium and two potassiums
(59,60).
In this case transport or release of magnesium is coupled
to transport or release of calcium, at least in mito-
chondria and endoplasmic or sarcpplasmic reticulum.
The eytosqlic calcium concentration is changed con-
siderably during these processes, which is important
for regulation of muscular contraction and cellular meta-
bolism (58). Since the intracellular magnesium is buf-
fered, the cytosolic magnesium concentration will not
be changed (33, 36), However, it cannot be excluded
that the properties Of mitochondria or endoplasmie
reticulum are changed by release of magnesium.
Magnesium uptake in the intestine
The daily magnesium intake varies considerably. The
main dietary sources of magnesium are green vegetables,
meat and seafood. However, depending on the technique
of cooking, large quantities of magnesium may be
extracted into water and thus lost. Therefore, the data
indicating an average daily intake of 15 mmol magnesium
must be regarded with caution. It is believed that the
amount of magnesium absorbed by the gut depends on
the amount of magnesium intake and is not affected by
the needs of the body, either in hypomagnesemia or
in hypermagnesemia. However, controversial results on
the effect of hormones on intestinal magnesium uptake
have been reported (see below). Clearly more systematic
studies are needed to decide the question of whether
the intestinal magnesium absorption is controlled by a
homeostatic mechanism. For details see the review of
Walser (9).
Intestinal magnesium uptake has been investigated pre-
ferentially in animals. As was found in rats with loops
isolated in vivo, magnesium is absorbed throughout the
whole intestine from the duodenum up to the colon.
It is believed that in this species most of the magnesium
uptake is located in the duodenum. The ileum and
colon absorb less magnesium than the duodenum, but
do not differ, one from the other (61, 62). In humans,
isolated perfused jejunum and ileum take up approxim-
ately the same amount of magnesium (63).
At present it cannot be decided by which mechanism
magnesium is absorbed in the intestine. Experiments
on the relation of magnesium absorption to luminal
magnesium concentration resulted in a nonlinear,
saturable funcion in all species investigated. These
were rat (62, 64, 65), sheep (66), and human (63). Un-
fortunately no Km values have been reported. This result
may be interpreted to mean that magnesium is taken up
by a "carrier" or a "channel" with limited capacity. Howr
ever, it could also mean that magnesium is taken up by
simple diffusion, which is reduced at higher magnesium
concentrations by a limited magnesium permeability.
Increasing Mg concentration decreases intestinal and
renal tubular water permeability (67, 68). Evidence for
magnesium uptake by "solvent drag" was obtained in
the rat ileum. Magnesium uptake was strictly deter-
mined by the magnitude and direction of transepi-
thelial water flux: sodium, urea and sugar stimulate
the uptake of water and magnesium. Mannitol inhibits
both processes (62). However, transepithelial magne-
sium transport takes place against a transmural potential
difference (PD). In the rat ileum, the PD is + 3 mV in
the absence and +11 mV in the presence of glucose
(62, 69). In the rat colon the average PD is 23 mV,
independently of glucose (62). In the sheep ileum, mag-
nesium uptake occurs at a transmural PD of + 10 to
+ 15mV(66,70>
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In order to analyse further the mechanisms of trans-
epithelial magnesium transport, it would be necessary
to calculate the magnesium equilibrium potential
according to the Nernst equation on both the mucosal
and the serosal side of the intestine. However, this
would require data on the magnesium ion concen-
tration of stool and within the cell, which are not
available at present. In stripped mucosa of rat duo-
denum, the total magnesium content is 8.5 mmol/kg
wet weight and the serum concentration is 0.95 minol/1
(71). Assuming 1) a water content of approximately
80% and 2) that 80% of the total magnesium is bound,
the cellular magnesium ion concentration could be in
the range of 1 mmol/1 cell water. This value is in agree-
ment with data determined for other tissues (33-35).
At an expected magnesium ion concentration of
2 mmol/1 stool water, the magnesium equilibrium
potential on the mucosal side of the cell is in the
range of + 9 mV. Since the measured mucosal trans-
membranal PD of rat ileum was approximately
-9 mV (69), magnesium uptake could be passively
driven by a total gradient of about 18 mV. This assump-
tion would also be true for a higher content of ionized
magnesium in stool. As a second step, magnesium is
extruded from the cell and taken up from the blood.
In serum the magnesium ion concentration should be
in the range of 0.5 mmol/1 at a total concentration of
0.95 mmol/1. The calculated magnesium equilibrium
potential would be approximately -9 mV. However,
since the measured serosal transmembranal PD of rat
jejunum was —20 mV, intracellular side negative (69),
magnesium has to be transported against a potential of
11 mV. Thus, magnesium extrusion should be an active
process. It has recently been demonstrated for the
rumen epithelium of sheep that magnesium transport
is dependent on metabolic energy (72). However, it
must be stated that the calculation of the magnesium
equilibrium potential is only tentative and is critically
dependent on the intracellular magnesium ion concen-
tration, which is not exactly known in this tissue. If the
intracellular magnesium ion concentration exceeds 2.2
mmol/1, the equilibrium potential and measured PD
would be approximately the same, and magnesium
extrusion could be passive.
In several species, intestinal magnesium uptake is in-
hibited by calcium. This has been reported for loops
of rat intestine perfused in vivo (73) and for sheep
intestine (66). The'inhibition of magnesium uptake may
be caused by a decrease in membrane permeability in-
duced by calcium or by competition of calcium and
magnesium for the same carrier. Unfortunately no
kinetic analysis has been reported by the investigators.
It should be mentioned that in humans calcium ex-
erted no effect on magnesium reabsorption in jejunum
perfused in vivo (63).
Phosphate is an additional factor determining mag-
reabsorption. At normal magnesium intakenesium
magnesium reabsorption is decreased by the forma-
tion of insoluble magnesium phosphate complexes
(74,75). The fat content of the intestinal contents
also influences magnesium absorption. It has long been
known that in man, steatorrhea is associated with in-
creased fecal losses of calcium and magnesium (76-80)
which is likely to be due in part to fecal fatty acid
magnesium soap formation. In more systematic
studies with rats (81) and new born infants (82, 83)
it has been shown that the nature and quantity of
fat intake determines magnesium reabsorption.
When poorly absorbable fats consituted a large pro-
portion of the diet, absorption of magnesium decreased
considerably.
Renal magnesium excretion
The kidney is the most important organ for regulation
of magnesium metabolism. If the magnesium intake is
high, the kidney excretes excess magnesium absorbed
from the intestine or mobilized from bone. When the
magnesium intake is low, negative balance can usually
be prevented by almost total renal conservation of the
element.
Renal handling of magnesium is determined by
glomerular filtration, resorption and eventually by
secretion. Unlike monovalent ions, magnesium is not
freely filterable. Since approximately 30% of the magne-
sium in the plasma is bound to protein, only 70% of the
serum magnesium is filterable. In the ultrafiltrate, as in
the serum, magnesium should exist in two physio-
chemical states: as the free ion and complexed (9).
The ligands might be citrate, phosphate, sulfate and
various organic acids. These complexes will be small
enough to pass the glomerular filter. Data on ionized
magnesium in the ultrafiltrate are not available.
Approximately 3.5% of the filtered magnesium is ex-
creted into the urine. Therefore the rest must be re-
absorbed. In micropuncture experiments it was found
that in the proximal tubule, magnesium reabsorption
is not isotonic, unlike sodium, potassium and calcium
reabsorption. In the rat, TF/P values of ultrafiltrated
magnesium increase with tubule length. Late proximal
TF/P values of 1.5-2.0 are reached (2, 84,85). Simil-
arly high TF/P values have been found in Psamommys
(86). For dogs, a TF/P value of 1.2 is reported (87).
The simultaneously determined TF/P inulin values were
always higher than that of magnesium and indicate that
magnesium is reabsorbed. In the proximal tubule approxi-
mately 20-30% of the filtered magnesium is reabsorbed
(84, 85,87) in contrast to sodium, potassium and
calcium, which are characterized by a 60% reabsprption
in the proximal tubule.
In the early-distal tubule the recovery of filtered magne-
sium was 15% in rats and 8% in dogs (85, 87). Thus it
J. Clin. Chem. Clin. Biochem. / Vol. 18, 1980 / No. 5
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could be concluded that the main part of magnesium
reabsorption, approximately 55% in rats and 63% in
dogs, is localized within/fettfe's loop. Micropuncture
of//enfe's loop in the region of the papilla showed that
the fraction of filtered magnesium there is not different
from the late proximal fraction (85). This has been
interpreted as evidence that 1) magnesium is not reab-
sorbed in the descending limb oflfenle's loop and 2) the
main part of magnesium reabsorption is localized in the
ascending limb ofHenle's loop.
The distal tubule obviously is not important for magne-
sium reabsorption in the rat and the dog. Late-distal and
in the collecting duct there is no further magnesium
reabsorption (85, 87, 88).
Tubular magnesium reabsorption is charaterized by a
limited capacity. In the rat, magnesium reabsorption
is near to saturation at physiological magnesium con-
centrations in serum (89). In the dog, maximal magne-
sium transport capacity is reached in the range of patho-
logically increased serum magnesium values. The Tm
value was 140 Mg/min - kg body weight (90, 91).
The question of whether mammals resemble aglomerular
fish in being able to secrete magnesium during anti-
diuresis is a matter of controversy at the moment. So
far, magnesium secretion has been produced in rats
or dogs only under the condition of an acute or chronic
hypermagnesemia or during a massive diuresis (92,
93). Other authors did not succeed in producing a
magnesium secretion under these conditions (94).
A possible site for magnesium secretion is the descending
limb ofHenle's loop. This was concluded from the
following findings: 1) micropuncture of the loop of
Henle at the papilla yielded 131% of the filtered mag^
nesium; 2) compared to control animals, the percent
magnesium reabsorption of the late proximal tubule
was unchanged (93). It is an open question whether
magnesium secretion also takes place at normal magne.
sium serum values. In the descending limb ofHenle's
loop, no net magnesium reabsorption could be demon-
strated under these conditions. In this case magnesium
secretion should be counterbalanced by magnesium
reabsorption of the same magnitude.
Tubular magnesium reabsorption is affected by several
factors. Expansion of the extracellular fluid by infusion
of sodium chloride results in increased magnesium excre-
tion produced by an inhibition of tubular magnesium
reabsorption (95, 96). Renal vasodilation produced by
intraarterial injection of acetylcholine or bradykinift
increases the excretion of sodium, calcium and magne-
sium (97-99). Acute administration of alcohol is
followed by an increased urinary excretion of magne-
sium, both in normal men and iii alcoholics (100). As
was shown by conventional clearance techniques in
dogs the acute as well as the chronic magnesuric effect
of alcohol is caused by an increase of filtered load due
to an elevation in GFR while per cent magnesium re-
absorption was unchanged (101). Interestingly alcohol-
ics are frequently magnesium deprived. Balance studies
with normomagnesemic nonalcoholics with a daily in-
take of 11 alcohol over a period of 18 days showed that
a negative magnesium balance developed due to a small
but significantly increased urinary magnesium excretion
and a decreased intestinal Mg absorption (103). However,
after some magnesium depletion, it appears that alcohol
has no further magnesiuric effect (103).
Ingestion or infusion of glucose inhibits tubular reabsorp-
tion of magnesium (104, 105). The mechanism remains
obscure. The effect of insulin and other hormones on renal
magnesium excretion is described below.
Diuretics affect urinary magnesium excretion. Furose-
mide, ethacrynic acid and mercurials all produce not
only a significant natriuresis, but also a magnesuria
(106—110). It is assumed that they inhibit magnesium
transport in the ascending limb of Henle's loop. In
osmotic diuresis, too, there is an increased magnesium
excretion (109). Acetazolamide (106) and thiazides
(107,110,111) have no effect on magnesium excretion
or at most a small one.
The mechanism of renal magnesium transport, like that
of the intestinal transport, is a matter of speculation.
Data are required on the concentration of ionized magne-
sium determined by micropuncture in tubular fluid and
serum. Furthermore, data on intracellular magnesium
ion concentrations in the various tubule segments are
also needed.
Hormonal regulation of magnesium metabolism
Parathyrin
As far as we know, parathyrin is the most important
hormone in the regulation of magnesium metabolism.
However, in contrast to calcium, its effect on magne-
sium metabolism is less clear, and has been the subject
of controversy (9).
In chronic parathyroidectomized rats, the serum concen-
tration of magnesium is decreased (112—114). In balance
studies on chronic parathyroidectomized rats, it was
found that intestinal uptake of magnesium and urinary
losses were increased. It was concluded that parathyrin
inhibits, directly or indirectly, intestinal magnesium
absorption and facilitates renal magnesium transport.
In the same study it was shown that the effects were
dependent on calcium intake. A high calcium intake
decreased intestinal magnesium absorption and increased
renal magnesium excretion (114,115). This may be ex-
plained, at least in part, by the findings that calcium
per se is known to inhibit intestinal (73) and renal magne-
sium transport (116). A further explanation for the
intestinal effect of parathyrin may be that the hormone
promotes renal synthesis of the active form of vitamin D,
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which specifically increases intestinal calcium absorp-
tion, so that magnesium reabsorption might be hindered.
As to the renal action of parathyrin, it was found to
stimulate renal magnesium reabsorption in parathyroid-
ectomized rats (91,117) or in intact dogs. As to the
intestinal effect of parathyrin and vitamin D, it should
be mentioned that contradictory results, i.e. an increase
in magnesium absorption, have been reported by other
authors (118-120).
In humans a renal effect of parathyrin was demon-
strated in patients with hypoparathyroidism. In these
patients, the urinary magnesium excretion was reduced
by repeated injection of parathyroid extracts (121).
In balance studies it was shown that in patients with
primary hyperparathyroidism serum magnesium is
usually unchanged and the magnesium balance remains
positive. Only in more severe cases is the serum
magnesium lowered so that the magnesium balance
becomes negative. These patients are characterized
by a paradoxical increase in renal magnesium excretion
(118,122,123). This may be explained by increased
bone mobilization by parathyrin which leads to
hypercalcemia; this, in turn, counteracts a parathyrin
mediated increase in magnesium reabsorption. After
partial parathyroidectomy, the increased renal losses
of magnesium are reduced to the normal range and the
magnesium balance becomes positive.
If magnesium metabolism were regulated directly by
the parathyroid gland, there could be a relation between
serum magnesium and secretion of parathyrin, as has
been established for calcium. In vivo experiments in
goats with parathyroid glands perfused in situ demon-
strated an inhibition of parathyrin secretion with
increasing magnesium (124). More detailed studies
in vitro with bovine parathyroid slices showed that
increasing calcium or magnesium concentrations in-
hibited the secretion of immunoreactive parathyrin.
On a molar basis, the potency of calcium was 2.5 times
better than that of magnesium.
Since in short term experiments the ions did not affect
the conversion of proparathyrin to parathyrin, it is
assumed that they inhibit the release rather than the
synthesis of parathyrin (125). In cell suspensions and
cell cultures of bovine parathyroid, physiological con-
centrations of calcium and magnesium depressed the
release of parathyrin and of the concomittant secretory
protein. Vice versa, lowering the calcium or magnesium
concentration in the medium increased parathyrin
secretion. In this model, there was no quantitative differ-
ence in the inhibitory action of calcium and magnesium
(126-128). Interestingly, the inhibitory effect of one
of these cations was increased by the presence of a
minimal concentration of the other cation. This inter-
dependence of calcium and magnesium was taken äs
evidence that both ions react with different membrane
receptors. Both receptors must be occupied before
secretion of parathyrin can be effectively controlled
(128).
'However, in patients with primary hypomagnesemia
with secondary hypocalcemia, the stimulatory effect
of low magnesium concentration on parathyrin secretion
is not present. In these patients the serum concentration
of immunoreactive parathyrin is normal or decreased.
After intravenous infusion of magnesium, but not of
calcium, the secretion rate of parathyrin is paradoxically
increased (129-132).
Vitamin D
Not many data on the interaction of vitamin D with
magnesium metabolism are available. In the older
literature it was reported that serum magnesium is
decreased by the administration of vitamin D (133—135),
while intestinal absorption of the ions is unchanged (74)
or even stimulated (133,136). In the intact and para-
thyroidectomized rat, renal magnesium excretion was
decreased by vitamin D and the magnesium balance was
positive (135,137). In-patients with chronic renal
failure, long term administration of the synthetic vitamin
D analogue 1-hydroxy-cholecalciferol had no effect on
intestinal magnesium uptake or serum magnesium, while
the lowered serum calcium was normalized (138, 139)..
In very recent studies in humans a small increase in
intestinal absorption and urinary excretion of Mg by
vitamin D (25-hydroxy-; 1,25-dihydroxy; 1-hydroxy-
cholecalciferol) with no change in Mg balance was found
(139a). On the other hand no correlation of net intestinal
Mg absorption with plasma 1,25-dihydroxy-cholecalciferol
concentration was found (139b). Probably, other factors
may play a role in the regulation of intestinal Mg absorp-
tion in humans.
Calcitonin
In mammals physiological doses of calcitonin have no
effect on magnesium metabolism. In rats pharmaco-
logical doses of calcitonin lower serum magnesium
(140,141). Other authors reported ä decreased urinary
excretion of the ion in rats (142—144). In human« in
contrast to rats pharmacological doses of calcitonin
produced a transient magnesuria (145,146). Since
magnesuria is paralleled by an enhanced natriufesis,
which by itself produces a magnesuria, the effect of
calcitonin on renal magnesium excretion may be un-
specific. Whether the reported different effect of
calcitonin in rats and humans is due to species differ-
ences remains to be clarified.
Mineralocorticoids
The effects of adrenal steroids on magnesium have only
been reported in the older literature. After adrenal-
ectomy, serum and tissue magnesium are increased
(113, 146—148). Acute administration of aldosterone
had no effect on urinary magnesium excretidii of
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adrenalectomized dogs (149). However, in several species,
long-term administration of aldosterone increased renal
magnesium excretion (150, 151) and normalized serum
as well as tissue magnesium levels (113,148). The long-
term effect of mineralocorticoids on magnesium may
be not a direct one, and has been explained as a conse-
quence of extracellular volume expansion by the sodium
retained (152). As already mentioned, extracellular
volume expansion inhibits tubular magnesium reabsorp-
tion (95, 96). This also explains why acute administration
of mineralocorticoids has no effect on renal magnesium
excretion in the dog (149). In acute experiments, gluco-
corticoids have no influence on renal magnesium excre-
tion of adrenalectomized dogs (149).
As could be expected from animal experiments, patients
with primary aldosteronism show an increased renal
excretion of magnesium. Also, aldosterone increases
urinary magnesium excretion when given to adrenal-
ectomized patients. The aldosterone effect could be
counteracted by spironolactone (153). In normal sub-
jects the acute infusion of aldosterone or cortisol pro-
duced no change in the magnesium clearance (154).
Thyroid hormone
Magnesium metabolism is also influenced by thyroid
hormone. In thyrotoxic rats, serum and skeletal muscle
magnesium are increased. Conversely, hypothyroid rats
treated with propylthiouracil had lower levels of serum
and muscle magnesium (113, 148,155).
In contrast to rats, low serum levels and increased renal
losses of magnesium have been found in hyperthyroid
patients, while in hyppthyroidism, serum magnesium
was increased and urinary magnesium excretion was
reduced (156,157). It cannot be said whether the differ-
ences in the results obtained in rats and in humans are
solely due to species differences, or caused by the
difference in pathögenesis of human and experimentally
induced disease.
Insulin
In rats with an ällöxäri- or streptozotocin-induced dia-
betes mellitus, duodenal reabsorption of calcium and
magnesium are reduced. At the same time, renal mag-
nesium excretion is increased. The renal magnesium
wasting results in a hypomagnesemia and a negative mag-
nesium balance (158—160). The reduced intestinal mag-
nesium uptake may be a consequence of the secondary
hyperparathyroidism that is frequently observed in
diabetic rats (158). The increased renal excretion of
magnesium might be caused by the osmotic diuresis
maintained by a ghicpsuria, which counteracts the pro-
moting effect of parathyriri on tubular magnesium
reabsorption.
Like the rats, diabetic patients suffer from lowered
serum magnesium and increased urinary loss of the
ion (161,162). In a routine investigation on 5100
patients it was found that hypomagnesemia was most
frequently associated with diabetes mellitus (7).
Adrenalin
Injection of a high dose of adrenalin caused hyper-
magnesemia in rats and ewes by a loss of intracellular
magnesium. Infusion of adrenalin at a dose of
40 Mg · kg"1 · h"1 into sheep caused hypomagnesemia
(163).
Hypomagnesemia
At low magnesium intake the kidney almost completely
reabsorbs magnesium. Thus, in adults small variations of
dietary magnesium intake usually do not produce a hypo-
magnesemia. Only an extreme reduction of the magne-
sium intake as is the case in fasting, or iatrogenic by long
term infusion of magnesium free solutions can hypo-
magnesemia be produced. More commonly, hypo-
magnesemia is observed as a result of reduced intestinal
uptake or decreased tubular reabsorption. Reasons for a
decreased intestinal uptake of magnesium are: removal
of the small intestine, chronic diarrhoea, various mal-
absorption syndromes. Increased renal losses of magne-
sium with a resulting hypomagnesemia have been
observed under the following conditions: after long
term therapy with diuretics, in the polyuria phase of
acute renal failure, in chronic alcoholism, and in diabetic
patients.
A rare cause of hypomagnesemia is a defect in intestinal
absorption (164—166) or renal tubular reabsorption
(167-169) of magnesium as a familial disorder. The
mechanism of these defects is obscure. Symptoms
indicating hypomagnesemia may be: increased neuro-
muscular excitability, carpopedal spasms, tetany. How-
ever, since hypomagnesemia in most cases does not
occur as an isolated symptom, but usually is associated
with hypocalceriiia and hypokalemia, the specificity of
these symptoms is an open question. For a more detailed
review on hypomagnesemia in patients see I.e. (9,
170-172).
The diagnosis of magnesium deficiency is not easy. When
magnesium intake is reduced or renal magnesium losses
are increased, the serum level of magnesium should be
lowered. However, this is not necessarily the case, since
the ionized part of serum magnesium representing only
1 % of total body magnesium is in equilibrium with
magnesium bound to bone, which contains approxim-
ately 50% of total body magnesium. Under these condi-
tions, magnesium is released from the bone so that the
lowered serum level is counterbalanced and may be
changed only within the limits of normal range. For
practical reasons, therefore, a magnesium deficit is
usually assumed that in hypomagnesemia. Indeed, a
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positive correlation of serum and bone magnesium has
been established in patients. However, in contrast to
bone, muscle magnesium seems to change independently
of serum magnesium (173). Furthermore, in uremic
patients with chronic renal failure, serum magnesium
has been found to be normal or mostly elevated,
whereas the bone magnesium content was considerably
diminished (174). Thus serum magnesium is not always
a reliable indicator of magnesium deficiency. Perhaps
the measurement of renal excretion of an intravenous
magnesium load would provide an additional aid in the
diagnosis of magnesium deficiency, provided that
1) circulation and renal function are normal and
2) water metabolism is in balance.
Multiple factors are involved in the mechanism of
secondary hypocalcemia in hypomagnesemia. One main
reason is the skeletal resistance to the calcemic action
of parathyrin. In patients with hypomagnesemia,
several authors could not restore the lowered values of
serum calcium by administration of parathyroid extract
(175—177). However, administration of magnesium
alone normalized the responsiveness to parathyroid
extract in these patients. It should be mentioned that
some authors failed to detect a skeletal resistance to
parathyrin in hypomagnesemia patients (178). Also in
animals such as the chicken (179) and the dog (180)
magnesium depletion is associated with hypocalcemia
that is less responsive to parathyroid extract and was
normalized by magnesium repletion. It should be noted
that in the magnesium depleted rat, hypo-, normo-
or hypercalcemia is observed, dependent on the calcium
content of the magnesium-deficient diet (181). However,
the skeletal resistance to parathyroid hormone was also
present in these animals (182).
A second reason for hypocalcemia as a consequence of
hypomagnesemia is an impaired function of the para-
thyroid gland. Blood levels of parathyrin were not
elevated as is to be expected in hypocalcemia but were
depressed or even undetectable under these conditions
(129,130,183). After administration of magnesium,
blood levels of parathyrin increased markedly (131,
132).
In contrast to humans, an isolated hypomagnesemia
can be produced in young rats by a magnesium-deficient
diet. After one week the first visible symptoms, the
formation of multiple edema and of erythema, can be
observed. Later, growth is retarded, tetany and paresis
develop, the circulating immunoglobulins are diminished,
the skin develops trophic lesions, calcemic precipitates
are formed in several organs such as kidney, heart, and
aorta, and occasionally a thymoma develops. In these
animals the hypomagnesemia is paralleled by a small but
significant reduction of intracellular magnesium. Thus,
at least in growing animals, hypomagnesemia indicates
magnesium.depletion (184).
When intracellular magnesium decreases during growth
under the conditions of magnesium deprivation, one
can expect dissociation of magnesium-RNA complexes.
In E. coli, the ribosomes disintegrate and growth is
retarded. Because of the defective growth, intracellular
magnesium is not further decreased. In addition, buffer-
ing of intracellular magnesium maintains intracellular
magnesium at a relatively constant level.
Magnesium depletion also affects sodium and potassium
metabolism. Mg deficient animals are characterized by
a rise of sodium and a fall of potassium in the muscle
(185-187) and heart (184,187). Since the width of the
zona glomerulosa of the adrenal cortex (188) and the
secretion of aldosterone (189) were found to increase,
in magnesium depleted rats, the changes in cellular
electrolyte contents were explained by hyperaldosteron-
ism (189). However, it is well known that aldosterone
enhances Na+ transport out of the cell and K* uptake
into the cell. Therefore, in Mg deficient rats, the anta-
gonistic effects of hyperaldosteronism and hypocorti-
cism (also found in Mg deficiency (189)) may be present.
The decrease of cellular potassium and increase of sodium
and calcium are also present in Yoshida ascites tumor
cells (190) and fibroblasts (191) grown in vitro in magne-
sium deficient media without any addition of aldo-
sterone. In this model the changed intracellular electro-
lyte concentrations have been explained by a change in
cellular permeability. In these cells the potassium efflux
was increased much more than potassium influx (190).
As a consequence of increased intracellular sodium levels,
the distribution of intracellular calcium is changed. It is
known that under these conditions heart and muscle
mitochondria exchange calcium against sodium (192).
The increase in cytosolic calcium is followed by an
increase in potassium permeability, at least in liver and
erythrocytes (193,194). Adenylate cyclase is activated
by an increase of cytosolic calcium up to 1 "4 mol/1,
as shown for synaptosomes in vitro (195). For the
mechanism see (196—198). Indeed, in Yoshida ascites
tumor cells grown in magnesium-deficient media, and
in several organs (heart, liver, adipose tissue) of magne-
sium deprived young rats, cellular cAMP was increased
(199, 200). With the model of the isolated perfused liver
it has been shown that an increase in cellular cAMP may
cause a further increase in potassium and calcium perme-
ability (201). Swelling and disruption of the cells finally
is prevented by an activation of (Na"1" + K^-ATPase due
to the increase in intracellular sodium, so that the higher
leak fluxes are counterbalanced by an increase to active
transport of sodium and potassium (190, 202).
In magnesium-deprived cells the rates of DNA, RNA and
protein biosynthesis are impaired (190,191). The same
effect is produced in Yoshida ascites tumor cells by the
ionophor X 537 A (203). Intraceflular sodium, calcium
and cAMP are also increased, but potassium is decreased
in X 537 -treated cells, äs in magnesium defioiency.
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From this it is concluded that the inhibition of DNA,
RNA and protein synthesis observed in magnesium
deprivation are primarily caused by the changes in intra-
cellular electrolyte concentrations. Secondarily, an
alteration in intracellular enzymes involved in protein
synthesis may occur. A reduced activity of elongation
factor 1 and 2 was found in lymphocytes from magne-
sium deficient rats (204). This may be a reason why the
effects of Mg-deficiency were only normalized by Mg in
conjunction with protein synthesis (24,190). In the
animal, several additional changes are superimposed on
these cellular events. Since in hypomagnesemia the com-
petition of magnesium with calcium is impaired, more
calcium permeates. Therefore calcium-dependent reac-
tions such as the release of catecholamines (205) are
activated. In magnesium-deprived rats an increased
release and urinary excretion of catecholamines is found
(206). Since catecholamines are known to activate
adenylate cyclase and to increase cAMP, the cellular
biochemical reactions of magnesium deficiency may
be enhanced by catecholamines. However, it is an open
question whether the described components of the
reaction mechanism in magnesium deficiency are ex-
pressed to the same degree in all cells and organs, since
they differ in cation permeability and adenylate cyclase
activity, and are characterized by a different sensitivity
to catecholamines.
Hypermagnesemia
After an acute oral or intravenous magnesium load, the
ion is excreted in the urine within 24—48 hours (106,
207). Therefore one can expect hypermagnesemia when
kidney function is considerably impaired and renal Tm
Mg is reached. Accordingly, acute and chronic renal
failure are the most common reasons for hypermagne-
semia. Hypermagnesemia can also be produced by a
massive magnesium overload, e.g. in the newborn after
magnesium therapy of the mother because of eclampsia
during parturition. The symptoms of hypermagnesemia
are related to nerves, muscle and heart. Depending on
the degree of magnesium intoxication, the myogenic
tonus decreases and muscle paralysis develops. At serum
concentrations of 3 mmol/1 deep tendon reflexes dis-
appear. At 5 mmol/1 muscle paralysis begins to include
respiratory muscles. The heart shows some ECG ab-
normalities and becomes bradycardic. Also, hypo-
tension develops. A detailed review on excess magne-
sium has been published very recently (208).
Magnesium intoxication could be caused by an increase
in intracellular magnesium and/or by the increased
extracellular magnesium. As mentioned in the chapter
"magnesium transport", non-growing cells show only
a magnesium exchange, but no net uptake of the ion.
In E. coli the increase in extracellular magnesium is
followed by an increased binding of the ion on the
extracellular surface of the cell membrane. No sub-
stantial change in intracellular magnesium could be
detected (53). A small increase in intracellular magne-
sium has no significance in cellular metabolism, since
1) intracellular magnesium is buffered, 2) the dependence
of several enzymes on magnesium is changed with the
pMg in such a way that large changes of the magnesium
concentrations are necessary before enzyme activation
is changed significantly, 3) the intracellular pMg is at
the pMg optimum of most magnesium-dependent cells
(19).
Therefore the symptoms of magnesium intoxication must
be primarily due to the increased extracellular magne-
sium. Presumably several calcium-dependent reactions
are inhibited competitively by high magnesium concen-
tration. Muscle paralysis during magnesium intoxication
is explained by inhibition of acetylcholine release in the
neuromuscular synapse and by a decrease in postsynaptic
excitability (208-211). The inhibition of cholinergic
transmission of the autonomous system is explained by
an analogous mechanism (210,212). Also, transmission
in adrenergic synapses is blocked by magnesium. This is
caused by inhibition of noradrenalin release and accelera-
tion of the noradrenalin reuptake (213-215). The
mechanism by which the PR intervals in the ECG are
prolonged so that a complete heart block and some-
times even heart arrest in systole may be observed, are
not well understood (208). The hypotension is caused
by dilatation of resistance vessels, which has been ex-
plained by a decreased excitability of the smooth muscles
and an inhibition of electro-mechanical coupling (216,
217).
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